We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026

IMDx Receives Certification to Develop, Manufacture IVD Devices

By LabMedica International staff writers
Posted on 21 Jun 2012
Intelligent Medical Devices (IMDx; Cambridge, United Kingdom) has received International Organization for Standardization (ISO) certification to design, develop, and manufacture in vitro diagnostic devices for the diagnosis of infectious diseases in molecular biology, and will obtain licenses to commercialize the tests in Canada. More...


IMDx underwent a stringent audit of its quality system to ISO 13485:2003 with the implementation of requirements from the Canadian Medical Devices Regulations. The audit included quality management system development, documentation review, preaudit, initial assessment, and clearance. The ISO 13485:2003 accreditation was received from the Laboratoire national de métrologie et d’essais (LNE/G-MED) and is accepted worldwide as the inclusive international standard that defines quality in the area of medical devices.

The IMDx portfolio of infectious disease diagnostics includes CE-marked tests for toxigenic Clostridium difficile, vancomycin-resistant enterococci, and Group B Streptococcus.

“Receiving this certification is a true testament to our dedication to making high quality products,” says Dr. Alice Jacobs, MD, chairman and CEO of IMDx. “Our mission at IMDx is to make a wide range of diagnostic tests available as broadly as possible. The ability to eventually commercialize our tests in Canada brings us closer to achieving the goal of improving healthcare worldwide.”

Related Links:
International Organization for Standardization
IntelligentMDX




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.